Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study.

Recchia F, Candeloro G, Desideri G, Necozione S, Recchia CO, Cirulli V, Rea S.

Cancer Med. 2012 Aug;1(1):89-95. doi: 10.1002/cam4.3. Epub 2012 May 31.


Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.

Yagata H, Kajiura Y, Yamauchi H.

Breast Cancer. 2011 Jul;18(3):165-73. doi: 10.1007/s12282-011-0254-9. Epub 2011 Feb 3. Review. Erratum in: Breast Cancer. 2012 Oct;19(4):369.


Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.


[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.


[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].

Yuan P, Xu BH, Wang JY, Ma F, Li Q, Zhang P, Fan Y, Li Q, Wang WM.

Zhonghua Zhong Liu Za Zhi. 2012 Jun;34(6):465-8. doi: 10. 3760/cma.j.issn.0253-3766.2012.06.014. Chinese.


Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.

Crump M, Gluck S, Tu D, Stewart D, Levine M, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Marlin S, Shepherd L, Pritchard KI.

J Clin Oncol. 2008 Jan 1;26(1):37-43. Epub 2007 Nov 19.


Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.

Ardavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, Chrysochoou M, Sotiropoulou A, Arnogiannaki N, Ioannidis G, Pissakas G, Rigatos G.

Oncologist. 2006 Jun;11(6):563-73.


Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.

Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S.

Expert Opin Investig Drugs. 2013 Mar;22(3):299-307. doi: 10.1517/13543784.2013.766715.


Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.

Ismaili N, Mellas N, Masbah O, Elmajjaoui S, Arifi S, Bekkouch I, Ahid S, Bazid Z, Tazi MA, Erraki A, El Mesbahi O, Benjaafar N, El Gueddari Bel K, Ismaili M, Afqir S, Errihani H.

Radiat Oncol. 2009 Apr 7;4:12. doi: 10.1186/1748-717X-4-12.


Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.


Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study.

Dazzi C, Cariello A, Rosti G, Tienghi A, Molino A, Sabbatini R, Aieta M, Frassineti GL, Vertogen B, Giovanis P, Marangolo M.

Haematologica. 2001 May;86(5):523-9.


Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.

Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S.

Bone Marrow Transplant. 2001 Jul;28(2):173-80.


3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.

Ferreira Filho AF, Crown J, Cardoso F, Nogaret JM, Duffy K, Dolci S, Rowan S, O'Higgins N, Batter V, Paesmans M, Piccart MJ, Di Leo A.

Anticancer Res. 2002 Jul-Aug;22(4):2471-6.


A systematic overview of chemotherapy effects in breast cancer.

Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.


Chemotherapy and concomitant irradiation in inflammatory breast cancer.

Tubiana-Mathieu N, Lejeune C, Bonnier P, Genet D, Adjadj DJ, Berda JF, Muracciole X, Delaby F, Clavere P, Benyoub A, Rhein B, Juin B, Piana L.

Anticancer Res. 2001 Jul-Aug;21(4B):3061-7.


Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946. Epub 2012 Jun 5.


Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results.

Colozza M, Gori S, Mosconi AM, Anastasi P, de Angelis V, Giansanti M, Mercati U, Aristei C, Latini P, Tonato M.

Am J Clin Oncol. 1996 Feb;19(1):10-7.


Supplemental Content

Support Center